Clinical Takeaway
In this phase 3 trial of 820 adults, the full-spectrum cannabis extract VER-01 was tested against placebo over 12 weeks for chronic low back pain, with longer follow-up phases extending to approximately one year. The trial was designed to assess both efficacy and safety in a condition that affects hundreds of millions of people and lacks reliably effective treatment options. Results from this rigorously controlled study provide clinical-grade evidence relevant to whether full-spectrum cannabis extracts represent a viable pharmacologic option for this patient population.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous evidence on full-spectrum cannabis extract efficacy for chronic low back pain, a condition affecting over 500 million people globally where current pharmacologic options demonstrate limited effectiveness and carry significant safety concerns. The large multicenter design with 820 participants and extended follow-up duration enables robust assessment of both efficacy and long-term safety profile, which is essential for informing clinical decision-making about cannabis-based therapeutics as an alternative treatment option. If efficacious, this work could expand the therapeutic arsenal for CLBP management and potentially reduce reliance on opioids and other pharmacotherapies associated with substantial adverse effects.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
🔬 This phase 3 trial of VER-01, a full-spectrum Cannabis sativa extract, addresses a genuine clinical need in chronic low back pain management where conventional pharmacotherapy often falls short or carries unacceptable risk profiles. While the enrollment of 820 participants and randomized placebo-controlled design represent methodological strengths, the abstract provided is incomplete, making it difficult to assess critical outcomes, effect sizes, adverse event rates, and whether benefits persisted meaningfully in the open-label extension phase, where expectancy bias becomes a significant confounder. Key clinical questions remain unanswered: how does efficacy compare to existing multimodal approaches including physical therapy and adjunctive medications, what is the cannabinoid profile and dose standardization of VER-01, and were there identifiable responder characteristics that might guide patient selection. Until full results are published and we can evaluate the magnitude of pain reduction, functional improvement, and safety profile in comparison to current standards of care, this trial’s clinical utility remains uncertain. In